mani
pathogen
take
advantag
depend
host
interact
hundr
extracellular
protein
glycosaminoglycan
heparan
sulphat
regul
homeostasi
use
heparan
sulphat
mean
adher
gain
access
cell
moreov
mucos
epithelia
respiratori
tract
protect
layer
mucin
polysaccharid
usual
sulphat
consequ
polydispers
natur
product
heparan
sulphat
alli
polysaccharid
heparin
found
involv
prevent
infect
rang
virus
includ
sassoci
coronaviru
strain
use
surfac
plasmon
reson
circular
dichroism
measur
interact
spike
protein
receptor
bind
domain
rbd
heparin
data
demonstr
interact
recombin
surfac
receptor
bind
domain
polysaccharid
implic
rapid
develop
firstlin
therapeut
repurpos
heparin
nextgener
tailormad
gagbas
antivir
surfac
receptor
bind
domain
bind
heparin
introduct
heparin
second
wide
use
drug
weight
global
formul
polydispers
heterogen
natur
product
unfraction
heparin
low
molecular
weight
heparin
heparinoid
clinic
approv
anticoagul
thrombot
excel
safeti
stabil
bioavail
pharmacokinet
profil
crucial
heparin
deriv
lack
signific
anticoagul
activ
underexploit
antivir
drug
class
despit
possess
broadspectrum
activ
multitud
distinct
virus
includ
coronavirida
sarsassoci
coronaviru
strain
addit
flavivirus
herp
influenza
hiv
tradit
drug
develop
process
slow
ineffect
emerg
public
health
threat
current
coronaviru
outbreak
make
repurpos
exist
drug
time
attract
altern
heparin
welltoler
anticoagul
pharmaceut
use
safe
medicin
year
alongsid
anticoagul
activ
abil
prevent
viral
infect
includ
coronavirida
describ
furthermor
close
relat
glycosaminoglycan
gag
member
heparan
sulphat
hs
known
bind
cov
surfac
protein
use
coronaviru
attach
target
cell
current
commerci
avail
medicin
product
design
treat
andor
prevent
infect
associ
new
coronaviru
outbreak
describ
preliminari
test
abil
rbd
bind
heparin
import
prerequisit
underpin
research
relat
develop
heparinbas
therapeut
residu
spike
protein
genbank
clone
upstream
ntermin
x
histag
prseta
express
vector
transform
express
compet
e
coli
neb
uk
protein
express
carri
e
coli
express
media
invitrogen
uk
hr
rpm
bacteri
pellet
suspend
ml
lysi
buffer
bugbust
protein
extract
reagent
merck
millipor
uk
contain
dnase
incub
room
temperatur
min
protein
purifi
inclus
bodi
use
imac
chromatographi
denatur
condit
oncolumn
protein
refold
perform
appli
gradient
decreas
concentr
denatur
agent
urea
extens
wash
protein
elut
use
mm
ph
mm
nacl
mm
imidazol
fraction
pool
bufferexchang
phosphatebuff
salin
pb
mm
nacl
mm
mm
ph
lonza
uk
use
sephadex
column
ge
healthcar
uk
recombin
protein
store
requir
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
march
http
doi
biorxiv
preprint
surfac
receptor
bind
domain
bind
heparin
circular
dichroism
cd
spectrum
rbd
pb
record
use
jasco
cd
spectromet
jasco
uk
spectral
manag
ii
softwar
jasco
uk
mm
pathlength
quartz
cuvett
hellma
usa
scan
nmmin
nm
resolut
throughout
rang
nm
spectra
obtain
mean
five
independ
scan
follow
instrument
calibr
camphorsulphon
acid
rbd
bufferexchang
prior
spectral
analysi
use
kda
vivaspin
centrifug
filter
sartoriu
germani
g
thrice
cd
spectra
collect
use
mgml
solut
pb
ph
spectra
heparin
porcin
mucos
heparin
deriv
oligosaccharid
collect
buffer
approxim
compar
concentr
sinc
dispers
materi
collect
data
analys
spectral
manag
ii
softwar
prior
process
graphpad
prism
use
second
order
polynomi
smooth
neighbour
secondari
structur
predict
calcul
use
bestsel
analysi
server
ensur
cd
spectral
chang
rbd
presenc
porcin
mucos
heparin
aris
addit
heparin
alon
known
possess
cd
spectrum
high
concentr
differ
spectrum
analys
theoret
cd
spectrum
result
arithmet
addit
cd
spectrum
rbd
heparin
differ
observ
experiment
cd
spectrum
rbd
mix
heparin
demonstr
chang
cd
spectrum
aros
conform
chang
follow
bind
porcin
mucos
heparin
human
produc
describ
duchesn
et
al
porcin
mucos
heparin
biotinyl
reduc
end
use
hydroxylamin
biotin
thermofish
uk
describ
thakar
et
al
heparin
mg
ml
react
hydroxylaminebiotin
mm
anilin
sigmaaldrich
uk
mm
acet
ph
h
free
biotin
remov
gelfiltr
chromatographi
sephadex
ge
lifesci
uk
multichannel
surfac
plasmon
reson
spr
instrument
instrument
canada
employ
gold
sensor
chip
plasma
clean
prior
derivat
selfassembl
monolay
mpeg
thiol
biotin
mpeg
form
incub
chip
mm
solut
reagent
molar
ratio
ethanol
hr
chip
rins
ethanol
place
instrument
pb
use
run
buffer
three
sens
fourth
background
channel
use
ismatec
pump
twenti
microgram
streptavidin
sigma
uk
ml
pb
inject
four
sensor
channel
subsequ
biotinheparin
ml
inject
three
sens
channel
bind
experi
use
pb
tween
vv
run
buffer
ligand
inject
three
sens
channel
dilut
concentr
indic
see
figur
sensor
surfac
bound
regener
wash
nacl
fisher
scientif
uk
howev
found
ineffectu
rbd
partial
regener
surfac
achiev
mm
hcl
vwr
uk
wv
sd
vwr
uk
found
remov
bound
protein
regener
wv
sd
fluidic
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
march
http
doi
biorxiv
preprint
surfac
receptor
bind
domain
bind
heparin
surfac
wash
mm
hcl
ensur
trace
deterg
remov
background
bind
underli
streptavidin
bound
mpegbiotin
mpeg
selfassembl
monolay
determin
inject
control
channel
respons
report
chang
plasmon
reson
wavelength
nm
three
control
channel
repres
averag
respons
well
characteris
heparinbind
protein
use
test
success
function
three
sens
channel
biotinheparin
inject
ml
nm
sens
channel
elicit
signific
respons
fig
inject
red
arrow
howev
nm
elicit
respons
control
channel
function
sole
streptavidin
shown
bound
remov
wash
nacl
done
previous
iasi
optic
biosensor
nm
rbd
inject
three
sens
channel
initi
decreas
signal
follow
increas
indic
bind
fig
red
arrow
initi
decreas
due
slightli
lower
refract
index
rbd
protein
solut
compar
pb
run
buffer
caus
neg
bulk
shift
demonstr
inject
nm
solut
control
channel
function
streptavidin
decreas
respons
follow
return
baselin
channel
return
run
buffer
fig
red
arrow
data
demonstr
rbd
protein
bind
specif
heparin
immobilis
reducingend
fail
bind
underli
streptavidin
ethyleneglycol
surfac
circular
dichroism
cd
spectroscopi
detect
chang
protein
secondari
structur
occur
solut
use
uv
radiat
upon
bind
conform
chang
detect
quantifi
use
spectral
deconvolut
inde
rbd
underw
conform
chang
presenc
heparin
figur
combin
helix
content
increas
global
betasheet
content
decreas
observ
chang
demonstr
rbd
interact
heparin
aqueou
solut
physiolog
signific
wherebi
major
chang
induc
heparin
associ
antiparallel
helix
content
basic
amino
acid
known
dictat
bind
protein
heparin
mind
primari
sequenc
analysi
express
protein
domain
analysi
model
rbd
structur
figur
show
sever
potenti
heparin
bind
site
importantli
these
patch
basic
amino
acid
expos
protein
surfac
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
march
http
doi
biorxiv
preprint
figur
interact
nm
rbd
immobilis
heparin
reduc
end
biotinyl
heparin
immobilis
streptavidin
functionalis
sensor
surfac
biotinheparin
control
pb
run
buffer
flow
rate
data
three
sens
channel
report
averag
respons
start
protein
inject
indic
blue
arrow
return
surfac
run
buffer
pbst
red
arrow
inject
nm
b
inject
nm
rbd
protein
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
march
http
doi
biorxiv
preprint
figur
structur
chang
rbd
observ
presenc
heparin
circular
dichroism
cd
spectroscopi
cd
spectra
spike
rbd
alon
black
heparin
red
phosphat
buffer
salin
ph
theoret
sum
spike
rbd
alon
heparin
control
interact
observ
dot
red
b
secondari
structur
increas
helix
decreas
antiparallel
secondari
structur
featur
calcul
bestsel
observ
spectrum
compar
theoret
summ
spectrum
rbd
presenc
heparin
figur
rbd
protein
model
basic
amino
acid
solvent
access
surfac
indic
dark
blue
observ
form
continu
patch
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
march
http
doi
biorxiv
preprint
surfac
receptor
bind
domain
bind
heparin
rapid
spread
repres
signific
challeng
global
health
author
current
approv
drug
treat
prevent
andor
mitig
effect
repurpos
exist
drug
time
appeal
strategi
heparin
welltoler
anticoagul
drug
use
success
year
limit
manag
side
effect
furthermor
heparin
belong
uniqu
class
pharmaceut
effect
antidot
avail
make
use
safer
studi
spike
protein
structur
behaviour
solut
vital
step
develop
effect
therapeut
abil
rbd
bind
pharmaceut
heparin
studi
use
spectroscop
techniqu
concert
molecular
model
data
show
rbd
bind
heparin
upon
bind
signific
structur
chang
induc
moreov
moieti
basic
amino
acid
residu
known
constitut
heparin
bind
domain
solvent
access
rbd
surfac
form
continu
patch
suitabl
heparin
bind
glycosaminoglycan
ubiquit
present
almost
mammalian
cell
class
carbohydr
central
strategi
employ
coronavirida
attach
host
cell
heparin
previous
shown
inhibit
sarsassoci
coronaviru
strain
cell
invas
concert
data
present
within
studi
support
utilis
glycosaminoglycanderiv
pharmaceut
sarsassoci
coronaviru
furthermor
studi
strongli
support
repurpos
heparin
deriv
antivir
agent
provid
rapid
countermeasur
current
outbreak
noteworthi
even
pharmaceuticalgrad
heparin
prepar
remain
polydispers
mixtur
natur
product
contain
anticoagul
nonanticoagul
saccharid
structur
latter
may
prove
invalu
resourc
nextgener
biolog
activ
antivir
agent
display
neglig
anticoagul
potenti
whilst
former
remain
tractabl
facil
chemic
enzymat
engin
strategi
ablat
anticoagul
activ
subfraction
exist
heparin
prepar
anticoagul
activ
proven
lowtox
profil
good
bioavail
industrialscal
manufactur
offlabel
patholog
provid
attract
strategi
quickli
effect
respond
develop
next
gener
heparinbas
therapeut
drug
amen
routin
parenter
administr
current
establish
rout
addit
direct
respiratori
tract
via
nasal
administr
use
nebulis
heparin
would
unlik
gain
signific
access
circul
thu
anticoagul
activ
heparin
event
engin
would
pose
problem
importantli
rout
administr
would
suitabl
prophylaxi
also
patient
mechan
ventil
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
march
http
doi
biorxiv
preprint
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
march
http
doi
biorxiv
preprint
